CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of CAMP4 Therapeutics Corporation (NASDAQ:CAMP) have earned an average rating of “Moderate Buy” from the seven analysts that are currently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and five have given a buy recommendation to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $8.60.

CAMP has been the topic of several research reports. Leerink Partners lifted their price target on CAMP4 Therapeutics from $8.00 to $9.00 and gave the company an “outperform” rating in a research report on Thursday, April 2nd. Rodman & Renshaw initiated coverage on CAMP4 Therapeutics in a research report on Tuesday, April 14th. They set a “buy” rating and a $7.00 price target on the stock. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of CAMP4 Therapeutics in a research report on Friday, March 6th.

CAMP4 Therapeutics Stock Performance

Shares of CAMP stock opened at $4.05 on Friday. CAMP4 Therapeutics has a fifty-two week low of $1.30 and a fifty-two week high of $7.75. The firm has a market cap of $210.30 million, a P/E ratio of -1.52 and a beta of 0.04. The business’s 50 day moving average price is $4.66 and its 200-day moving average price is $4.59.

CAMP4 Therapeutics (NASDAQ:CAMP) last released its quarterly earnings results on Thursday, March 5th. The Wireless communications provider reported ($0.87) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($0.56). CAMP4 Therapeutics had a negative net margin of 2,298.54% and a negative return on equity of 162.49%. The firm had revenue of $0.35 million for the quarter. As a group, equities analysts predict that CAMP4 Therapeutics will post -0.78 EPS for the current year.

Institutional Investors Weigh In On CAMP4 Therapeutics

Hedge funds have recently made changes to their positions in the company. Janus Henderson Group PLC raised its stake in CAMP4 Therapeutics by 35.9% during the fourth quarter. Janus Henderson Group PLC now owns 6,307,636 shares of the Wireless communications provider’s stock valued at $38,807,000 after buying an additional 1,666,666 shares during the last quarter. EcoR1 Capital LLC purchased a new position in CAMP4 Therapeutics during the fourth quarter valued at $1,992,000. Balyasny Asset Management L.P. purchased a new position in CAMP4 Therapeutics during the fourth quarter valued at $14,938,000. 683 Capital Management LLC purchased a new position in CAMP4 Therapeutics during the fourth quarter valued at $775,000. Finally, Adage Capital Partners GP L.L.C. raised its stake in CAMP4 Therapeutics by 11.3% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 2,181,679 shares of the Wireless communications provider’s stock valued at $13,374,000 after buying an additional 220,895 shares during the last quarter.

About CAMP4 Therapeutics

CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location.